

BioCardia, Inc.  
Form NT 10-K  
April 02, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

---

**FORM 12b-25**

---

**NOTIFICATION OF LATE FILING**

(Check One)    Form 10-K    Form 20-F    Form 11-K    Form 10-Q  
                  Form 10-D    Form N-SAR    Form N-CSR

For Period Ended: December 31, 2018

Transition Report on Form 10-K  
Transition Report on Form 20-F  
Transition Report on Form 11-K  
Transition Report on Form 10-Q  
Transition Report on Form N-SAR

For the Transition Period Ended:

**Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I — REGISTRANT INFORMATION**

**BIOCARDIA, INC.**

**(Full Name of Registrant)**

**N/A**

**(Former Name if Applicable)**

**125 Shoreway Road, Suite B**

**(Address of Principal Executive Office (*Street and Number*))**

**San Carlos, CA 94070**

**(City, State and Zip Code)**

---

**PART II — RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
-

**PART III — NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

BioCardia, Inc. (“BioCardia” or the “Company”) was unable to file its Annual Report on Form 10-K for the year ended December 31, 2018 (the “Form 10-K”) within the prescribed time period without unreasonable effort or expense. Due to unanticipated delays in reviewing and finalizing the filing, the Company filed the Form 10-K on April 1, 2019, but such filing occurred after the 5:30 p.m. Eastern time EDGAR filing deadline on such date.

Since the filing has already been completed, the Company has complied with the requirement set forth in Rule 12b-25 of the Securities and Exchange Act of 1934, as amended, that the filing be made no later than the fifteenth calendar day following the prescribed due date.

---

**PART IV — OTHER INFORMATION**

(1) Name and telephone number of person to contact in regard to this notification

|                      |                    |                           |
|----------------------|--------------------|---------------------------|
| <b>David McClung</b> | <b>650</b>         | <b>226-0120</b>           |
| <b>(Name)</b>        | <b>(Area Code)</b> | <b>(Telephone Number)</b> |

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or (2) Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes No

**BIOCARDIA, INC.**

**(Name of Registrant as Specified in Charter)**

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date April 2, 2019 By/s/ David McClung  
David McClung  
Chief Financial Officer

**INSTRUCTION:** The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

**ATTENTION**

**Intentional misstatements or omissions of fact constitute Federal Criminal Violations  
(See 18 U.S.C. 1001).**